Valerio Therapeutics (FR:ALVIO)
:ALVIO
Want to see FR:ALVIO full AI Analyst Report?
ALVIO Stock Chart & Stats
€0.06
<€0.01(1.53%)
At close: 4:00 PM EST
€0.06
<€0.01(1.53%)
Day’s Range― - ―
52-Week Range€0.04 - €0.31
Previous CloseN/A
Volume8.86K
Average Volume (3M)1.36M
Market Cap
€99.52M
Enterprise Value€77.01M
Total Cash (Recent Filing)€1.05M
Total Debt (Recent Filing)€7.61M
Price to Earnings (P/E)―
Beta-1.14
Next EarningsN/A
EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)N/A
Shares Outstanding499,448,300
10 Day Avg. Volume527,429
30 Day Avg. Volume1,357,798
Financial Highlights & Ratios
PEG Ratio0.05
Price to Book (P/B)10.27
Price to Sales (P/S)8.28
P/FCF Ratio40.89
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Revenue And Gross Margin RecoveryA strong 40.6% revenue rebound in 2025 combined with high gross margins (~67–71%) indicates the company’s R&D outputs and clinical efforts are translating into higher realizable value. Durable margin strength supports scalable economics if revenue growth continues and underpins long-term product-level sustainability.
Turning Operating & Free Cash Flow PositiveOperating cash flow turned positive (~1.8M) and free cash flow was positive (~0.5M) in 2025 after years of burn, marking a structural improvement in cash generation. This improvement materially reduces near-term funding dependence and provides a more durable runway for clinical programs if cash generation is sustained.
Focused Oncology Small‑Molecule PlatformA focused clinical-stage platform targeting DNA/RNA mechanisms gives Valerio a differentiated scientific niche and potential high barriers to entry. Concentrated expertise and a lean team (38 employees) can accelerate development efficiency and preserve capital, benefits that remain relevant across the medium term.
Bears Say
High Leverage And Balance-Sheet VolatilityMaterial increase in leverage (debt-to-equity ~3.7x) and prior swings into negative equity reflect a volatile balance sheet that constrains financial flexibility. Elevated leverage increases refinancing and covenant risk, limiting the company’s ability to fund trials or scale programs without dilutive or costly financing.
Ongoing Net LossesDespite operational improvement, the company remained loss-making (~-4.9M in 2025), indicating recurring expense intensity relative to revenue. Continued negative earnings mean reliance on external capital or sustained cash generation; this persistent loss profile is a durable headwind until consistent profitability is achieved.
Inconsistent Cash Generation HistoryAlthough 2025 showed positive operating and free cash flow, prior multi-year cash burn and volatile FCF highlight inconsistent cash generation. If R&D or trial spending ramps, cash flow could quickly reverse, making funding stability and program continuity contingent on either sustained FCF or external financing.
ALVIO FAQ
What was Valerio Therapeutics’s price range in the past 12 months?
Valerio Therapeutics lowest stock price was €0.04 and its highest was €0.31 in the past 12 months.
What is Valerio Therapeutics’s market cap?
Valerio Therapeutics’s market cap is €99.52M.
When is Valerio Therapeutics’s upcoming earnings report date?
The company’s upcoming earnings report date is not yet available.
How were Valerio Therapeutics’s earnings last quarter?
Currently, no data Available
Is Valerio Therapeutics overvalued?
According to Wall Street analysts Valerio Therapeutics’s price is currently Overvalued.
Does Valerio Therapeutics pay dividends?
Valerio Therapeutics does not currently pay dividends.
What is Valerio Therapeutics’s EPS estimate?
Valerio Therapeutics’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Valerio Therapeutics have?
Valerio Therapeutics has 499,448,300 shares outstanding.
What happened to Valerio Therapeutics’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of Valerio Therapeutics?
Currently, no hedge funds are holding shares in FR:ALVIO
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Valerio Therapeutics
Headquartered in Paris, France, and founded in 1997, Valerio Therapeutics S.A. (known as Onxeo SA until June 2023) is a clinical-stage biotechnology company dedicated to the global research and development of oncology treatments. Their focus is on targeting the DNA repair processes crucial for tumor survival. The company's offerings include Beleodaq, an approved medication for peripheral T-cell lymphoma. Their development pipeline features AsiDNA, which is progressing through Phase 1 clinical trials for metastatic melanoma and is also being evaluated for relapsed ovarian cancer through a research collaboration with Gustave Roussy. Furthermore, Valerio Therapeutics is advancing OX401, a preclinical program targeting DNA damage response and immuno-oncology, along with its proprietary platON decoy oligonucleotide platform. The firm also holds a licensing agreement with Acrotech Biopharma LLC.
Technical Analysis
Innate Pharma SA
―
Transgene
―
OSE Immunotherapeutics SA
―
GenSight Biologics SA
―
Cellectis SA
―